Adorisio Rachele, Mencarelli Erica, Cantarutti Nicoletta, Calvieri Camilla, Amato Liliana, Cicenia Marianna, Silvetti Massimo, D'Amico Adele, Grandinetti Maria, Drago Fabrizio, Amodeo Antonio
Heart Failure Clinic-Heart Failure, Heart Transplant, Mechanical Circulatory Support Unit, Department of Pediatric Cardiology and Cardiac Surgery, Heart and Lung Transplant, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Pediatric Cardiology and Cardiac Arrhythmias/Syncope Unit, Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
J Clin Med. 2020 Oct 1;9(10):3186. doi: 10.3390/jcm9103186.
Duchenne muscular dystrophy (DMD) cardiomyopathy (DCM) is characterized by a hypokinetic, dilated phenotype progressively increasing with age. Regular cardiac care is crucial in DMD care. Early recognition and prophylactic use of angiotensin converting enzyme inhibitors (ACEi) are the main stay therapeutic strategy to delay incidence of DMD-DCM. Pharmacological treatment to improve symptoms and left ventricle (LV) systolic function, have been widely implemented in the past years. Because of lack of DMD specific drugs, actual indications for established DCM include current treatment for heart failure (HF). This review focuses on current HF strategies to identify, characterize, and treat DMD-DCM.
杜兴氏肌营养不良症（DMD）心肌病（DCM）的特征是运动功能减退、扩张型表型，并随年龄增长而逐渐加重。在DMD护理中，定期心脏护理至关重要。早期识别并预防性使用血管紧张素转换酶抑制剂（ACEi）是延缓DMD-DCM发病的主要治疗策略。在过去几年中，已广泛采用改善症状和左心室（LV）收缩功能的药物治疗。由于缺乏DMD特异性药物，目前DCM的实际适应症包括当前的心力衰竭（HF）治疗。本综述重点关注目前用于识别、表征和治疗DMD-DCM的HF策略。
